Clinical Trial

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Study acronym: ROSE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 14, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Study Objectives are: To assess the safety of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after concomitant osimertinib and irradiation of tumor sites. To assess the efficacy of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease. To investigate Quality of Life during and after irradiation therapy and concomitant osimertinib.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-10-20; most recent amendment 2026-01-13.
Status change: Recruiting → Active, Not Recruiting 2025-07-08
Status change: Not Yet Recruiting → Recruiting 2022-05-17
Trial Details
NCT Number NCT05089916
Lead Sponsor AIO-Studien-gGmbH
Collaborators: AstraZeneca
Conditions NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression
Enrollment 42 participants
Start Date 2022-01-20
Primary Completion 2026-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-14